Haemonetics (NYSE:HAE) Posts Earnings Results, Beats Expectations By $0.03 EPS

Haemonetics (NYSE:HAE) released its earnings results on Thursday. The medical instruments supplier reported $1.12 EPS for the quarter, beating analysts’ consensus estimates of $1.09 by $0.03, Briefing.com reports. The business had revenue of $345.50 million for the quarter, compared to analysts’ expectations of $342.57 million. Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. The firm’s revenue was up 8.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.99 earnings per share. Haemonetics updated its FY25 guidance to $4.45-4.75 EPS and its FY 2025 guidance to 4.450-4.750 EPS.

Haemonetics Trading Up 1.0 %

Haemonetics stock opened at $87.42 on Friday. Haemonetics has a 1 year low of $70.25 and a 1 year high of $97.97. The firm’s 50 day moving average price is $75.88 and its 200-day moving average price is $82.65. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.76 and a quick ratio of 2.33. The stock has a market cap of $4.47 billion, a P/E ratio of 39.22, a PEG ratio of 1.22 and a beta of 0.32.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Citigroup reduced their price target on Haemonetics from $94.00 to $85.00 and set a “neutral” rating on the stock in a research report on Thursday, August 22nd. Bank of America started coverage on Haemonetics in a research report on Wednesday, September 11th. They issued a “neutral” rating and a $85.00 target price for the company. BTIG Research began coverage on Haemonetics in a research report on Tuesday, September 10th. They set a “buy” rating and a $112.00 price target on the stock. Barrington Research reiterated an “outperform” rating and issued a $108.00 price objective on shares of Haemonetics in a report on Friday. Finally, CL King started coverage on Haemonetics in a research report on Friday, September 13th. They set a “buy” rating and a $116.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Haemonetics has an average rating of “Moderate Buy” and a consensus target price of $107.88.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.